Clinical Trial Update: Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating SHR-1819 for efficacy and safety in adults with severe atopic dermatitis is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• SHR-1819

Snippet

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Conditions: Moderate to Severe Atopic Dermatitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING